• Corpus ID: 211196989

COSTS AND RATIONING OF INSULIN AND DIABETES SUPPLIES : FINDINGS FROM THE 2018 T 1 INTERNATIONAL PATIENT SURVEY

@inproceedings{2019COSTSAR,
  title={COSTS AND RATIONING OF INSULIN AND DIABETES SUPPLIES : FINDINGS FROM THE 2018 T 1 INTERNATIONAL PATIENT SURVEY},
  author={},
  year={2019}
}
  • Published 2019
  • Medicine

Figures and Tables from this paper

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE‐3 (Recombinant Human INsulin Equivalence‐3) study

To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of proposed biosimilar insulin 70/30 (Biocon's Insulin‐70/30) and HUMULIN® 70/30 (HUMULIN‐70/30; Eli Lilly and Company, IN).

Pricing for Medicine Innovation: A Regulatory Approach to Support Drug Development and Patient Access

The United States represents the world’s largest market for pharmaceutical drugs. It is also the only advanced economy in the world that does not regulate drug prices. There is no upper threshold for

Public Perspectives on Anti-Diabetic Drugs: Exploratory Analysis of Twitter Posts

This study suggests that there is a fear of not having access to anti-diabetic drugs due to cost or physical availability and highlights the impact of the sacrifices made to access anti-Diabetic drugs.

Analysis of Diabetes Apps to Assess Privacy-Related Permissions: Systematic Search of Apps

Assessing the levels of privacy of mobile apps for diabetes to contribute to the raising of awareness of privacy issues for app users, developers, and governmental data protection regulators confirms the necessity of educating patients and health care providers and raising their awareness regarding the privacy aspects of diabetes apps.

Open-Source Technology for Real-Time Continuous Glucose Monitoring in the Neonatal Intensive Care Unit: Case Study in a Neonate With Transient Congenital Hyperinsulinism

Off-label use of real-time continuous glucose monitoring in a newborn with prolonged hypoglycemia secondary to transient congenital hyperinsulinism during the perinatal period and the use of an open-source app for glucose monitoring is described.

Profits, Innovation and Financialization in the Insulin Industry

The list prices of analogue insulin medicines in the United States have soared during the past decade. In the wake of high-profile cases of prescription medicine “price-gouging”, such as Mylan’s

References

SHOWING 1-10 OF 34 REFERENCES

Cost-Related Insulin Underuse Among Patients With Diabetes

This survey study examines the association of higher insulin costs with nonadherence in patients with diabetes with a history of type 2 diabetes and finds that insulin costs are higher when patients do not follow treatment.

Production costs and potential prices for biosimilars of human insulin and insulin analogues

Treatment with biosimilar RHI and insulin NPH could cost less than US$72 per year and with insulin analogues ≤US$133 per year, and widespread availability at estimated prices may allow substantial savings globally.

Access to insulin: patients will pave the way.

Evidence and AIDS activism: HIV scale-up and the contemporary politics of knowledge in global public health

  • C. Colvin
  • Political Science
    Global public health
  • 2014
What new forms of evidence and activism will be required to address the challenges of the scaling-up era of HIV treatment and prevention are examined.

Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes

Among young patients with type 1 diabetes, insulin pump therapy, compared with insulin injection therapy, was associated with lower risks of severe hypoglycemia and diabetic ketoacidosis and with better glycemic control during the most recent year of therapy.

Constraints and challenges in access to insulin: a global perspective.

Insulin: discovery and controversy.

Their experiments produced an extract of pancreas that reduced the hyperglycemia and glycosuria in dogs made diabetic by the removal of their pancreases, and a procedure for extraction from the entire Pancreas without the need for duct ligation, which was successful for treating humans with diabetes.

Reduction in hemoglobin A1C with real-time continuous glucose monitoring: results from a 12-week observational study.

This observational study showed that home use of real-time GCM was safe and well tolerated and associated with a clinically and statistically significant reduction in HbA1c.